We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




3D Genome Mapping Tool to Improve Diagnosis and Treatment of Genetic Diseases

By LabMedica International staff writers
Posted on 11 Nov 2025

Standard laboratory tests often fail to detect complex DNA rearrangements that underlie many genetic diseases. More...

To bridge this diagnostic gap, researchers have developed a 3D chromosome mapping method that can uncover previously hidden structural variants with remarkable precision.

This breakthrough approach, developed by researchers from the University of Washington School of Medicine (Seattle, WA, USA), could redefine the diagnosis and management of genetic disorders. Unlike traditional one-dimensional DNA sequencing, which reads genetic code linearly, the new technique captures the three-dimensional structure of chromosomes inside the nucleus. This spatial mapping, known as genomic proximity mapping (GPM), is based on Hi-C sequencing and reveals how different regions of DNA physically interact. These interactions can expose deletions, duplications, and rearrangements that remain invisible to conventional sequencing technologies.

In the study published in The Journal of Molecular Diagnostics (Elsevier), the researchers applied GPM to DNA samples from 123 patients with suspected genetic conditions. The method accurately identified all known large chromosomal variants (110 deletions or duplications and 27 rearrangements) with 100% concordance compared to standard tests. Additionally, GPM uncovered 12 novel structural variants that conventional methods had missed, including cryptic rearrangements and complex multi-chromosomal events.

The technology also detected low-level mosaicism, where different cells in a patient carry different genetic changes—an important capability for accurate diagnosis and prognosis. Moreover, GPM requires less DNA than other advanced techniques such as optical genome mapping (OGM) or long-read sequencing (LRS), making it more practical for use on preserved or low-quality tissue samples.

“GPM offers broad clinical benefits. It enables high-resolution, comprehensive genomic characterization, even from compromised samples such as low-quality or archived preserved tissue,” said co-lead investigator Yajuan J. Liu, PhD. “As genomic medicine moves toward precision diagnostics, this new tool addresses current limitations in genetic testing, improving diagnostics and empowering doctors to provide personalized treatment, tailored monitoring, better prognosis, and improved family counseling.”

Related Links:
University of Washington School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
Automatic CLIA Analyzer
Shine i6000
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.